Principal Investigator
Macarena De La Fuente
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20260396
Clinical Trial Summary
Phase III trial of radiotherapy followed by adjuvant temozolomide in combination with the IDH inhibitor vorasidenib vs. placebo in IDH-mutated newly-diagnosed grade 3 astrocytomas
Phase
Phase III
Funding Agency/Sponsor
National Cooperative Group
Disease
Neurological Cancer
Contact Information
Phone Number
+1 (305) 2437261